Orexo submits application to FDA for expanded label of ZUBSOLV®

Uppsala, Sweden – October 13, 2014 – Orexo AB (publ) announces today that it has
submitted an application to the U.S. Food and Drug Administration (FDA) for an
expanded label of ZUBSOLV (buprenorphine/naloxone CIII sublingual tablet) to
include initiation of treatment for opioid dependence. Orexo anticipates a
potential approval of the expanded label during the third quarter 2015.

The application for initiation of treatment is supported by the data from the
ISTART and OX219-007 studies. In the full dataset, Orexo found no difference
when comparing ZUBSOLV and generic buprenorphine monotherapy, when used as
treatment for the induction of buprenorphine maintenance
therapy[1] (http://file///C:/Users/user/BEATA/Orexo/141013/Press_release_Orexo_I
n 
duction_file_2014-10-13.docx#_ftn1).

“The FDA submission constitutes an important milestone for ZUBSOLV. Today we
take an important next step in the evolution of the product, applying for a new
indication and expanded label. A label including initiation of treatment will
enhance product differentiation and enable Orexo to educate physicians in how to
optimally use ZUBSOLV from the first day of treatment.” said Nikolaj Sørensen,
CEO and President of Orexo AB.

In a survey performed by Orexo among DATA2000 waivered physicians, who are less
active in treating opioid dependent patients, initiation of treatment was cited
as the main challenge when treating patients for opioid dependence by more than
40-percent of the respondents. 58-percent of the physicians said more education
would be a main driver for increasing their use of buprenorphine based
treatment. An induction label would allow Orexo to customize the education to
meet the specific needs of these physicians to increase their comfort in
treating patients suffering from opioid dependence.

Nikolaj Sørensen, CEO and President of Orexo AB, noted “Many patients suffering
from opioid dependence have difficulties in finding waivered physicians, with an
expanded label Orexo can take an active role to encourage and educate the
waivered, but not active, prescribers in initiation of treatment and improve
access to treatment for patient suffering from opioid dependence.”

For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com

About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery. The company is commercializing its proprietary product, ZUBSOLV
sublingual tablets, for maintenance treatment of opioid dependence, in the
United States. The ZUBSOLV sublingual tablet is a novel formulation of
buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual
technologies. Orexo has a portfolio of two approved and revenue generating
products currently marketed under license in the US, EU and Japan. Orexo AB,
with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange and its
American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S.
under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com.

About ZUBSOLV®
ZUBSOLV (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for
the maintenance treatment of opioid dependence and should be used as part of a
comprehensive treatment plan, which includes counseling and psychosocial
support. Treatment should be initiated under the direction of physicians who are
certified under the Drug Addiction Treatment Act of 2000, and who have been
assigned a unique identification number (“X” number).

ZUBSOLV sublingual tablets can be abused in a manner similar to other opioids,
legal or illicit. Clinical monitoring appropriate to the patient’s level of
stability is essential. Liver function tests should be monitored before and
during treatment. Children who take ZUBSOLV sublingual tablets can have severe,
possibly fatal, respiratory depression. Emergency medical care is critical. Keep
ZUBSOLV sublingual tablets out of the sight and reach of children.

Adverse events commonly observed with the sublingual administration of
buprenorphine/naloxone sublingual tablets during clinical trials and post
-marketing experience are headache, nausea, vomiting, hyperhidrosis,
constipation, signs and symptoms of withdrawal, insomnia, pain and peripheral
edema.

Further information on ZUBSOLV can be found at www.zubsolv.com.

Important Safety Information

  · Keep ZUBSOLV in a secure place away from children. If a child accidentally
takes ZUBSOLV, this is a medical emergency and can result in death. Get
emergency help right away

  · ZUBSOLV can cause serious and life-threatening breathing problems. Call your
doctor right away or get emergency help if (a) you feel faint, dizzy, or
confused; (b) your breathing gets much slower than is normal for you; (c) you
feel sleepy and uncoordinated; (d) you have blurred vision; (e) you have slurred
speech; (f) you cannot think well or clearly; or (g) you have slowed reflexes
and breathing. In an emergency, have family members tell the emergency
department staff that you are physically dependent on an opioid and are being
treated with ZUBSOLV

  · The most common side effects of ZUBSOLV include: headache, drug withdrawal
syndrome, nausea, decrease in sleep (insomnia), vomiting, pain, increased
sweating, swelling of the extremities, and constipation. Tell your doctor about
any side effect that bothers you or that does not go away

  · Do not switch from ZUBSOLV to other medicines that contain buprenorphine
without talking with your doctor. The amount of buprenorphine in a dose of
ZUBSOLV is not the same as the amount of buprenorphine in other medicines that
contain buprenorphine. Your doctor will prescribe a starting dose of
buprenorphine that may be different than other buprenorphine-containing
medicines you may have been taking

  · ZUBSOLV contains an opioid that can cause physical dependence. Do not stop
taking ZUBSOLV without talking to your doctor. You could become sick with
uncomfortable withdrawal signs and symptoms because your body has become used to
this medicine. Physical dependence is not the same as drug addiction. ZUBSOLV is
not for occasional or "as needed" use

  · An overdose, and even death, can happen if you take benzodiazepines,
sedatives, tranquilizers, or alcohol while using ZUBSOLV. Ask your doctor what
you should do if you are taking one of these. You should not drink alcohol while
taking ZUBSOLV, as this can lead to loss of consciousness or even death

  · Do not inject ("shoot-up") ZUBSOLV. Injecting ZUBSOLV may cause life
-threatening infections and other serious health problems. Injecting ZUBSOLV may
cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea,
anxiety, sleep problems, and cravings

  · Before taking ZUBSOLV, tell your doctor about all the medicines you take,
including prescription and over-the-counter medicines, vitamins, and herbal
supplements

  · Before taking ZUBSOLV, tell your doctor if you are pregnant or plan to
become pregnant. It is not known if ZUBSOLV will harm your unborn baby. If you
take ZUBSOLV while pregnant, your baby may have symptoms of withdrawal at birth.
Talk to your doctor if you are pregnant or plan to become pregnant

  · Before taking ZUBSOLV, tell your doctor if you are breastfeeding or plan to
breastfeed. ZUBSOLV can pass into your breast milk and may harm the baby. Talk
to your doctor about the best way to feed your baby if you take ZUBSOLV. Monitor
your baby for increased sleepiness and breathing problems

  · Do not drive, operate heavy machinery, or perform any other dangerous
activities until you know how ZUBSOLV affects you. Buprenorphine can cause
drowsiness and slow reaction times. This may happen more often in the first few
weeks of treatment when your dose is being changed, but can also happen if you
drink alcohol or take other sedative drugs when you take ZUBSOLV

  · ZUBSOLV is a controlled substance (CIII) because it contains buprenorphine,
which can be a target for people who abuse prescription medicines or street
drugs. Keep your ZUBSOLV in a safe place to protect it from theft. Never give
your ZUBSOLV to anyone else; it can cause death or harm them. Selling or giving
away this medicine is against the law

  · To report negative side effects associated with taking ZUBSOLV, please call
1-888-982-7658. You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see full Prescribing Information (http://zubsolv.com/pdf/zubsolvFullPI
-patient.pdf#1) and Medication
Guide (http://zubsolv.com/pdf/zubsolvMedicationGuide-patient.pdf#1) for ZUBSOLV.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 08:00 am CET on October 13, 2014.

----------------------------------------------------------------------

[1] (http://file///C:/Users/user/BEATA/Orexo/141013/Press_release_Orexo_Inductio
n 
_file_2014-10-13.docx#_ftnref1) Results from ISTART (OX219-006) and OX219-007
studies are available in a press release June 23, 2014 on www.orexo.com